These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21855118)

  • 1. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.
    Hyman DM; Zhou Q; Arnold AG; Grisham RN; Iasonos A; Kauff ND; Spriggs D
    Gynecol Oncol; 2011 Nov; 123(2):196-9. PubMed ID: 21855118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
    Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
    Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).
    Herzog TJ; Sill MW; Walker JL; O'Malley D; Shahin M; DeGeest K; Weiner SA; Mutch D; DeBernardo RL; Lentz SS
    Gynecol Oncol; 2011 Mar; 120(3):454-8. PubMed ID: 21168198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
    Kummar S; Oza AM; Fleming GF; Sullivan DM; Gandara DR; Naughton MJ; Villalona-Calero MA; Morgan RJ; Szabo PM; Youn A; Chen AP; Ji J; Allen DE; Lih CJ; Mehaffey MG; Walsh WD; McGregor PM; Steinberg SM; Williams PM; Kinders RJ; Conley BA; Simon RM; Doroshow JH
    Clin Cancer Res; 2015 Apr; 21(7):1574-82. PubMed ID: 25589624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
    Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study.
    McGonigle KF; Muntz HG; Vuky J; Paley PJ; Veljovich DS; Greer BE; Goff BA; Gray HJ; Malpass TW
    Cancer; 2011 Aug; 117(16):3731-40. PubMed ID: 21815133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
    Coleman RL; Sill MW; Bell-McGuinn K; Aghajanian C; Gray HJ; Tewari KS; Rubin SC; Rutherford TJ; Chan JK; Chen A; Swisher EM
    Gynecol Oncol; 2015 Jun; 137(3):386-91. PubMed ID: 25818403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
    Pennington KP; Walsh T; Harrell MI; Lee MK; Pennil CC; Rendi MH; Thornton A; Norquist BM; Casadei S; Nord AS; Agnew KJ; Pritchard CC; Scroggins S; Garcia RL; King MC; Swisher EM
    Clin Cancer Res; 2014 Feb; 20(3):764-75. PubMed ID: 24240112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
    Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
    Alsop K; Fereday S; Meldrum C; deFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G
    J Clin Oncol; 2012 Jul; 30(21):2654-63. PubMed ID: 22711857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
    van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
    Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
    Lord R; Rauniyar J; Morris T; Condon O; Jones R; Miller R; Hall M; Lofts F; Glasspool RM; Hudson E
    Int J Gynecol Cancer; 2020 Jul; 30(7):1026-1033. PubMed ID: 32321768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
    Cowan M; Swetzig WM; Adorno-Cruz V; Pineda MJ; Neubauer NL; Berry E; Lurain JR; Shahabi S; Taiym D; Nelson V; O'Shea KL; Kocherginsky M; Matei D
    Gynecol Oncol; 2021 Oct; 163(1):57-63. PubMed ID: 34419285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Not Available].
    Gladieff L; Lyonnet DS; Lortholary A; Leary A; Genestie C; Ray-Coquard I
    Bull Cancer; 2017 May; 104 Suppl 1():S16-S23. PubMed ID: 28625311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term topotecan therapy in recurrent or persistent ovarian cancer.
    Cormio G; Loizzi V; Gissi F; Camporeale A; De Mitri P; Leone L; Putignano G; Selvaggi L
    Eur J Gynaecol Oncol; 2011; 32(2):153-5. PubMed ID: 21614902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG
    Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
    Monk BJ; Grisham RN; Banerjee S; Kalbacher E; Mirza MR; Romero I; Vuylsteke P; Coleman RL; Hilpert F; Oza AM; Westermann A; Oehler MK; Pignata S; Aghajanian C; Colombo N; Drill E; Cibula D; Moore KN; Christy-Bittel J; Del Campo JM; Berger R; Marth C; Sehouli J; O'Malley DM; Churruca C; Boyd AP; Kristensen G; Clamp A; Ray-Coquard I; Vergote I
    J Clin Oncol; 2020 Nov; 38(32):3753-3762. PubMed ID: 32822286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma.
    Piura B; Rabinovich A
    Int J Gynecol Cancer; 2005; 15(4):612-7. PubMed ID: 16014114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.